IP Verse

Methods And Compositions For Treating Vitiligo - EP3752134

The patent EP3752134 was granted to Centre Hospitalier Universitaire DE Nice on Dec 4, 2024. The application was originally filed on Feb 15, 2019 under application number EP19705955A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3752134

CENTRE HOSPITALIER UNIVERSITAIRE DE NICE
Application Number
EP19705955A
Filing Date
Feb 15, 2019
Status
Granted And Under Opposition
Nov 1, 2024
Grant Date
Dec 4, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HGFSep 3, 2025HGFADMISSIBLE

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0368684
DESCRIPTIONUS2014068797
DESCRIPTIONUS4816567
DESCRIPTIONUS5981732
DESCRIPTIONUS6046321
DESCRIPTIONUS6075181
DESCRIPTIONUS6107091
DESCRIPTIONUS6150584
DESCRIPTIONUS6365354
DESCRIPTIONUS6410323
DESCRIPTIONUS6566131
DESCRIPTIONUS6566135
DESCRIPTIONUS6982321
DESCRIPTIONUS7087409
DESCRIPTIONUS8697359
DESCRIPTIONWO2006003388
DESCRIPTIONWO2006030220
DESCRIPTIONWO9311161
INTERNATIONAL-SEARCH-REPORTWO9950299
OPPOSITIONWO2013109974
OPPOSITIONWO2018119288

Non-Patent Literature (NPL) Citations (36) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CHRISTEN et al., The Journal of Immunology, (20030000), vol. 171, pages 8838 - 6845-
DESCRIPTION- DICARLO et al., Nucleic Acids Res., (20130000), vol. 41, pages 4336 - 4343-
DESCRIPTION- FABRE et al., PLoS Negl. Trop. Dis., (20140000), vol. 8, page e2671-
DESCRIPTION- FRIGERIO et al., Nature Medicine, (20020000), vol. 8, pages 1414 - 1420-
DESCRIPTION- GUO et al., Development, (20140000), vol. 141, pages 707 - 714-
DESCRIPTION- HWANG et al., PLoS One, (20130000), vol. 8, page e68708-
DESCRIPTION- LEPE V et al., Arch Dermatol., (20030500), vol. 139, no. 5, pages 581 - 5-
DESCRIPTION- MA et al., Cell Res., (20140000), vol. 24, pages 122 - 125-
DESCRIPTION- MALI et al., Science, (20130000), vol. 339, pages 823 - 826-
DESCRIPTION- MASHIKO et al., Dev. Growth Differ., (20140000), vol. 56, pages 122 - 129-
DESCRIPTION- NIU et al., Cell, (20140000), vol. 156, pages 836 - 843-
DESCRIPTION- ORIMOTO et al., J Immunol, (20040000), vol. 173, pages 7017 - 7024-
DESCRIPTION- PASSERON T et al., Arch Dermatol., (20040900), vol. 140, no. 9, pages 1065 - 9-
DESCRIPTION- PASSERON T et al., Dermatol Clin., (20170000), vol. 35, pages 163 - 170-
DESCRIPTION- RHODE et al., J. Immunol., (20050000), vol. 175, no. 6, pages 3516 - 24-
DESCRIPTION- ROEP et al., Clinical and Experimental immunology, (20030000), vol. 159, pages 338 - 343-
DESCRIPTION- SARKAR et al., Diabetes, (20120200), vol. 61, no. 2, pages 438 - 46-
DESCRIPTION- SARKAR et al., Diabetes, (20120200), vol. 81, no. 2, pages 436 - 46-
DESCRIPTION- TAIEB A et al., Br J Dermatol., (20130100), vol. 168, no. 1, pages 5 - 19-
DESCRIPTION- TAIEB, Dermatol Clin., (20130000), vol. 35, pages 163 - 170-
DESCRIPTION- UNO et al., Roep et al Clinical and Experimental Immunology, (20030000), vol. 159, pages 338 - 343-
DESCRIPTION- VAN HAITEREN et al., Diabetologia, (20050000), vol. 48, pages 75 - 82-
DESCRIPTION- YANG et al., J. Mol. Cell Biol., (20140000), vol. 6, pages 97 - 99-
DESCRIPTION- ZETSCHE et al., "Cpfl is a Single RNA-guided Endonuclease of a Class 2 CRISPR-Cas System", Cell, (20150000), vol. 163, pages 1 - 13-
EXAMINATION- TULIC MERI K. ET AL, "Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo", NATURE COMMUNICATIONS, vol. 10, no. 1, doi:10.1038/s41467-019-09963-8, (20190516), URL: https://www.nature.com/articles/s41467-019-09963-8, XP093089275
INTERNATIONAL-SEARCH-REPORT- WIJTMANS MAIKEL ET AL, "Towards small-molecule CXCR3 ligands with clinical potential", CHEMMEDCHEM, WILEY-VCH, DE, (20120208), vol. 3, no. 6, doi:10.1002/CMDC.200700365, ISSN 1860-7179, pages 861 - 872, XP002668990 [A] 1-4 * page 865, column l, paragraph 2 *
INTERNATIONAL-SEARCH-REPORT- WANG X X ET AL, "Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo", BRITISH JOURNAL OF DERMATOLOGY, OXFORD : WILEY-BLACKWELL, UK, (20160601), vol. 174, no. 6, doi:10.1111/BJD.14416, ISSN 0007-0963, pages 1318 - 1326, XP009506920 [A] 1-4 * page 1323, paragraph l * * page 1325, paragraph first *
OPPOSITION- EHLERT J E,ET AL, "Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping", The Journal of Immunology, American Association of Immunologists, (20041115), vol. 173, no. 10, ISSN 0022-1767, pages 6234 - 6240, XP002344010-
OPPOSITION- RICHMOND JILLIAN M ET AL, "CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice.", Journal of Investigative Dermatology, Elsevier, (20170401), vol. 137, no. 4, ISSN 1523-1747, pages 982 - 985, XP002778748-
OPPOSITION- WIJTMANS MAIKEL ET AL, "Towards small-molecule CXCR3 ligands with clinical potential", ChemMedChem Communications, Wiley-VCH, DE, DE , (20080101), vol. 3, no. 6, doi:10.1002/cmdc.200700365, ISSN 1860-7179, pages 861 - 872, XP002668990
OPPOSITION- Windmüller C, Zech D, Avril S, Boxberg M, Dawidek T, Schmalfeldt B, Schmitt M, Kiechle M, Bronger H, "CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients", ONCOGENESIS, Nature Publishing Group, US, US , vol. 6, no. 5, doi:10.1038/oncsis.2017.29, ISSN 2157-9024, pages e331 - e331, XP093313823
OPPOSITION- Tulic Meri K., Cavazza Elisa, Cheli Yann, Jacquel Arnaud, Luci Carmelo, Cardot-Leccia Nathalie, Hadhiri-Bzioueche Hanene, Abbe Patricia, Gesson Maéva, Sormani Laura, Regazzetti Claire, Beranger Guillaume E., Lereverend Cedric, Pons Caroline, Khemis Abdallah, Ballotti Robert, Bertolotto Corine, Rocchi Stéphane, Passeron Thierry, "Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo", Nature Communications, vol. 10, no. 1, doi:10.1038/s41467-019-09963-8, XP093089275
OPPOSITION- LASAGNI LAURA ET AL, "An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.", Journal of Experimental Medicine, Rockefeller University Press, US, US , (20030602), vol. 197, no. 11, doi:10.1084/jem.20021897, ISSN 0022-1007, pages 1537 - 1549, XP002246737
OPPOSITION- Smith Jeffrey S., Alagesan Priya, Desai Nimit K., Pack Thomas F., Wu Jiao-Hui, Inoue Asuka, Freedman Neil J., Rajagopal Sudarshan, "C-X-C Motif Chemokine Receptor 3 Splice Variants Differentially Activate Beta-Arrestins to Regulate Downstream Signaling Pathways", Molecular Pharmacology, (20170801), vol. 92, no. 2, doi:10.1124/mol.117.108522, ISSN 0026-895X, pages 136 - 150, XP093313821
OPPOSITION- M. Rashighi, P. Agarwal, J. M. Richmond, T. H. Harris, K. Dresser, M.-W. Su, Y. Zhou, A. Deng, C. A. Hunter, A. D. Luster, J. E. Harris, "CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo", Science Translational Medicine, (20140212), vol. 6, no. 223, doi:10.1126/scitranslmed.3007811, ISSN 19466234, pages 223ra23 - 223ra23, XP055152548
OPPOSITION- Rashighi Rashighi Mehdi Mehdi, Harris John E, "Interfering with the IFN-gamma/CXCL10 pathway to develop new targeted treatments for vitiligo", Annals of Translational Medicine, AME Publishing Company, US, US , (20151201), vol. 3, no. 21, doi:10.3978/j.issn.2305-5839.2015.11.36, ISSN 2305-5839, pages 343 - 343, XP093046088

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents